Therapeutic potential of somatic cell nuclear transfer for degenerative disease caused by mitochondrial DNA mutations

Gareth D. Greggains; Lisa M. Lister; Helen A.L. Tuppen; Qi Zhang; Louise H. Needham; Nilendran Prathalingam; Louise A. Hyslop; Lyndsey Craven; Zbigniew Polanski; Alison P. Murdoch; Douglass M. Turnbull; Mary Herbert

doi:10.1038/srep03844

Therapeutic potential of somatic cell nuclear transfer for degenerative disease caused by mitochondrial DNA mutations

Gareth D. Greggains, Lisa M. Lister, Helen A.L. Tuppen, Qi Zhang, Louise H. Needham, Nilendran Prathalingam, Louise A. Hyslop, Lyndsey Craven, Zbigniew Polanski, Alison P. Murdoch, Douglass M. Turnbull, Mary Herbert

Research output: Contribution to journal › Article › Research › peer-review

17 Citations (Scopus)

Abstract

Induced pluripotent stem cells (iPSCs) hold much promise in the quest for personalised cell therapies. However, the persistence of founder cell mitochondrial DNA (mtDNA) mutations limits the potential of iPSCs in the development of treatments for mtDNA disease. This problem may be overcome by using oocytes containing healthy mtDNA, to induce somatic cell nuclear reprogramming. However, the extent to which somatic cell mtDNA persists following fusion with human oocytes is unknown. Here we show that human nuclear transfer (NT) embryos contain very low levels of somatic cell mtDNA. In light of a recent report that embryonic stem cells can be derived from human NT embryos, our results highlight the therapeutic potential of NT for mtDNA disease, and underscore the importance of using human oocytes to pursue this goal.

Original language	English
Article number	3844
Number of pages	10
Journal	Scientific Reports
Volume	4
DOIs	https://doi.org/10.1038/srep03844
Publication status	Published - 24 Jan 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/srep03844Licence: CC BY-NC-SA

Cite this

Greggains, G. D., Lister, L. M., Tuppen, H. A. L., Zhang, Q., Needham, L. H., Prathalingam, N., Hyslop, L. A., Craven, L., Polanski, Z., Murdoch, A. P., Turnbull, D. M., & Herbert, M. (2014). Therapeutic potential of somatic cell nuclear transfer for degenerative disease caused by mitochondrial DNA mutations. Scientific Reports, 4, Article 3844. https://doi.org/10.1038/srep03844

@article{723d8ac0b7a143779c8de76d01dbec71,

title = "Therapeutic potential of somatic cell nuclear transfer for degenerative disease caused by mitochondrial DNA mutations",

abstract = "Induced pluripotent stem cells (iPSCs) hold much promise in the quest for personalised cell therapies. However, the persistence of founder cell mitochondrial DNA (mtDNA) mutations limits the potential of iPSCs in the development of treatments for mtDNA disease. This problem may be overcome by using oocytes containing healthy mtDNA, to induce somatic cell nuclear reprogramming. However, the extent to which somatic cell mtDNA persists following fusion with human oocytes is unknown. Here we show that human nuclear transfer (NT) embryos contain very low levels of somatic cell mtDNA. In light of a recent report that embryonic stem cells can be derived from human NT embryos, our results highlight the therapeutic potential of NT for mtDNA disease, and underscore the importance of using human oocytes to pursue this goal.",

author = "Greggains, {Gareth D.} and Lister, {Lisa M.} and Tuppen, {Helen A.L.} and Qi Zhang and Needham, {Louise H.} and Nilendran Prathalingam and Hyslop, {Louise A.} and Lyndsey Craven and Zbigniew Polanski and Murdoch, {Alison P.} and Turnbull, {Douglass M.} and Mary Herbert",

note = "Funding Information: We thank the patients who donated oocytes for use in this research. We also thank the Research Nurses Maria Nesbitt and Linda Burgess, and the embryology and clinical team at Newcastle Fertility Centre. We acknowledge help and advice given by Dr Shoukhrat Mitalipov, Oregon Health & Science University. The work was funded by the Medical Research Council (Grant Reference Number G0601157) and the Wellcome Trust (Grant Reference Number 096919/Z/11/Z).",

year = "2014",

month = jan,

day = "24",

doi = "10.1038/srep03844",

language = "English",

volume = "4",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Therapeutic potential of somatic cell nuclear transfer for degenerative disease caused by mitochondrial DNA mutations

AU - Greggains, Gareth D.

AU - Lister, Lisa M.

AU - Tuppen, Helen A.L.

AU - Zhang, Qi

AU - Needham, Louise H.

AU - Prathalingam, Nilendran

AU - Hyslop, Louise A.

AU - Craven, Lyndsey

AU - Polanski, Zbigniew

AU - Murdoch, Alison P.

AU - Turnbull, Douglass M.

AU - Herbert, Mary

N1 - Funding Information: We thank the patients who donated oocytes for use in this research. We also thank the Research Nurses Maria Nesbitt and Linda Burgess, and the embryology and clinical team at Newcastle Fertility Centre. We acknowledge help and advice given by Dr Shoukhrat Mitalipov, Oregon Health & Science University. The work was funded by the Medical Research Council (Grant Reference Number G0601157) and the Wellcome Trust (Grant Reference Number 096919/Z/11/Z).

PY - 2014/1/24

Y1 - 2014/1/24

N2 - Induced pluripotent stem cells (iPSCs) hold much promise in the quest for personalised cell therapies. However, the persistence of founder cell mitochondrial DNA (mtDNA) mutations limits the potential of iPSCs in the development of treatments for mtDNA disease. This problem may be overcome by using oocytes containing healthy mtDNA, to induce somatic cell nuclear reprogramming. However, the extent to which somatic cell mtDNA persists following fusion with human oocytes is unknown. Here we show that human nuclear transfer (NT) embryos contain very low levels of somatic cell mtDNA. In light of a recent report that embryonic stem cells can be derived from human NT embryos, our results highlight the therapeutic potential of NT for mtDNA disease, and underscore the importance of using human oocytes to pursue this goal.

AB - Induced pluripotent stem cells (iPSCs) hold much promise in the quest for personalised cell therapies. However, the persistence of founder cell mitochondrial DNA (mtDNA) mutations limits the potential of iPSCs in the development of treatments for mtDNA disease. This problem may be overcome by using oocytes containing healthy mtDNA, to induce somatic cell nuclear reprogramming. However, the extent to which somatic cell mtDNA persists following fusion with human oocytes is unknown. Here we show that human nuclear transfer (NT) embryos contain very low levels of somatic cell mtDNA. In light of a recent report that embryonic stem cells can be derived from human NT embryos, our results highlight the therapeutic potential of NT for mtDNA disease, and underscore the importance of using human oocytes to pursue this goal.

UR - http://www.scopus.com/inward/record.url?scp=84893131589&partnerID=8YFLogxK

U2 - 10.1038/srep03844

DO - 10.1038/srep03844

M3 - Article

C2 - 24457623

AN - SCOPUS:84893131589

SN - 2045-2322

VL - 4

JO - Scientific Reports

JF - Scientific Reports

M1 - 3844

ER -

Therapeutic potential of somatic cell nuclear transfer for degenerative disease caused by mitochondrial DNA mutations

Abstract

UN SDGs

Access to Document

Other files and links

Cite this